Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hahn Offers Upbeat User-Fee Prediction At AdvaMed Conference

Executive Summary

The US FDA commish praised the medical device community's work in response to the COVID-19 pandemic and predicted that communication developed with industry during the crisis may ease upcoming MDUFA negotiations.

You may also be interested in...



FDA Makes 2nd Attempt At Virtual MDUFA Public Meeting

For the second time in the past few months the US agency has rescheduled a webcast of a public meeting meant to start MDUFA V user-fee negotiations.

Neovasc Plans Next Steps After Thumbs Down From FDA Panel

FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.

Court Tosses Manufacturer’s Bid For Medicare Coverage

The US Court of Appeals for the Ninth Circuit found that Sensory NeuroStimulation Inc., which makes a device to treat restless leg syndrome, hadn’t exhausted all administrative remedies.

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel